Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
T-cell-engaging therapies for myeloma are linked to a high burden of prolonged, low-grade infectious complications, especially with bispecific therapy and particularly after BCMA-directed treatment.”
Title: Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma
Authors: Julia Mersi, Lara Burow, Xiang Zhou, Florian Eisele, Matthias Fante, Christine Riedhammer, August Stich, Nora Isberner, Nazia Afrin, Johannes Duell, Max S. Topp, Hermann Einsele, Johannes M. Waldschmidt, K. Martin Kortüm, Leo Rasche
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
